DNTH
Dianthus Therapeutics Inc

1,250
Mkt Cap
$3.51B
Volume
528,414.00
52W High
$88.02
52W Low
$13.37
PE Ratio
-19.18
DNTH Fundamentals
Price
$78.85
Prev Close
$78.90
Open
$78.72
50D MA
$53.84
Beta
1.04
Avg. Volume
629,526.92
EPS (Annual)
-$4.20
P/B
6.91
Rev/Employee
$22,130.44
$1,188.52
Loading...
Loading...
News
all
press releases
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Key Points5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter...
Nasdaq News: Markets·2h ago
News Placeholder
More News
News Placeholder
HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH
HighVista Strategies LLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 241.9% during the third quarter, according to the company in its most recent disclosure...
MarketBeat·2d ago
News Placeholder
Dianthus Therapeutics, Inc. $DNTH is Fairmount Funds Management LLC's Largest Position
Fairmount Funds Management LLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 22.2% in the third quarter, according to the company in its most recent filing...
MarketBeat·2d ago
News Placeholder
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH
Boothbay Fund Management LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·3d ago
News Placeholder
Dianthus Therapeutics Hits Early Go in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm
Dianthus Therapeutics (NASDAQ:DNTH) said it has made an early go decision to continue its CAPTIVATE Phase 3 trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP...
MarketBeat·3d ago
News Placeholder
Braidwell LP Purchases Shares of 835,057 Dianthus Therapeutics, Inc. $DNTH
Braidwell LP acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...
MarketBeat·3d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 33,830 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of...
MarketBeat·5d ago
News Placeholder
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares...
MarketBeat·5d ago
<
1
2
...
>

Latest DNTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.